Saturday 17 October 2026
Export SIBN’s income statement to Excel — free account
SiBone
SIBN Healthcare Medical Devices
SiBone’s revenue for fiscal 2025 (year ended December 2025) was $200.9 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 15.2%, EPS grew 35.7%, free cash flow grew 60.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
19.68
0.23
−1.16%
Follow SIBN
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 5 | 2 | 4 | 4 | 2 | 5 | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
7.18 | 4.04 | 6.40 | 1.85 | 6.28 | 9.05 | 4.07 | 1.69 | — | — |
P/S ratio |
4.22 | 3.48 | 5.77 | 4.28 | 8.17 | 11.84 | 7.89 | 3.00 | 1.45 | 1.45 |
Altman Z″-Score (non-manufacturers) |
1.52 | 0.77 | 1.23 | (3.34) | 1.11 | 4.67 | (1.10) | 3.70 | (12.01) | (9.59) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(3.08) | (2.74) | (2.79) | (2.74) | 3.84 | (2.81) | (0.58) | (2.46) | (3.30) | — |
P/Operating CF |
490.26 | 493.52 | (348.64) | (67.24) | (57.90) | (110.23) | (58.80) | (26.29) | (29.45) | (29.45) |
P/B ratio |
4.77 | 3.48 | 4.73 | 4.63 | 5.48 | 5.13 | 8.43 | 1.84 | 0.00 | 0.00 |
Price to Tangible BV |
4.77 | 3.48 | 4.73 | 4.63 | 5.48 | 5.13 | 8.43 | 1.84 | 0.00 | 0.00 |
EV/Sales |
3.66 | 2.80 | 4.84 | 3.71 | 6.94 | 9.82 | 7.11 | 1.64 | 2.09 | 2.09 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(1,090.93) | (37.68) | (35.93) | (9.48) | (15.82) | (23.50) | (15.13) | (6.27) | (8.79) | (8.79) |
EV/FCF |
(81.02) | (20.43) | (25.36) | (7.72) | (13.62) | (21.69) | (14.05) | (5.89) | (8.20) | (8.20) |
Quick Ratio |
7.03 | 6.54 | 8.01 | 5.57 | 9.55 | 15.59 | 5.51 | 14.51 | 3.96 | 2.53 |
Current Ratio |
8.55 | 7.66 | 9.01 | 6.50 | 10.41 | 16.20 | 5.94 | 15.11 | 4.46 | 2.71 |
Net Debt/EBITDA |
5.76 | 3.17 | 2.87 | 1.11 | 2.33 | 4.24 | 1.50 | 7.58 | (1.02) | (0.09) |
Debt/Assets |
14.91% | 15.38% | 15.65% | 22.32% | 18.36% | 17.68% | 33.52% | 28.13% | 108.01% | 74.32% |
Debt/Equity |
0.20 | 0.21 | 0.21 | 0.36 | 0.26 | 0.23 | 0.62 | 0.43 | (0.30) | (0.27) |
Asset Turnover |
0.86 | 0.73 | 0.72 | 0.61 | 0.44 | 0.43 | 0.53 | 0.64 | 1.28 | 1.12 |
Operating CF/Net income |
0.04 | 0.40 | 0.43 | 0.68 | 0.70 | 0.70 | 0.82 | 0.83 | 0.76 | 0.81 |
Capex/Depreciation |
(2.97) | 11.56 | (4.79) | (2.45) | (1.74) | (1.67) | (2.37) | (0.96) | (0.37) | (0.33) |
Interest Coverage |
(8.50) | (10.25) | (13.56) | (21.15) | (9.63) | (6.32) | (7.27) | (2.34) | (2.80) | (5.31) |
| (10.97%) | (18.38%) | (32.38%) | (52.64%) | (37.25%) | (37.61%) | (50.13%) | 89.08% | 19.35% | 17.29% | |
| (8.06%) | (13.42%) | (22.34%) | (35.20%) | (27.35%) | (25.69%) | (30.06%) | (20.02%) | (61.22%) | (54.71%) | |
ROIC |
(21.38%) | (42.06%) | (74.41%) | (102.96%) | (144.08%) | (194.61%) | (215.31%) | (107.88%) | 0.00% | 0.00% |
Return on Tangible Assets |
(8.91%) | (15.38%) | (21.25%) | (46.41%) | (33.68%) | (20.88%) | (39.74%) | (13.51%) | (82.32%) | (80.60%) |
Average Days of Receivables |
54.34 | 59.95 | 57.69 | 70.92 | 57.68 | 67.70 | 63.56 | 55.93 | 56.41 | 51.59 |
Research and Development Expense of Revenue |
8.68% | 9.91% | 10.82% | 12.81% | 13.80% | 12.89% | 10.82% | 9.71% | 11.49% | 15.15% |
Selling, General and Administrative Expense of Revenue |
82.00% | 90.21% | 101.75% | 128.45% | 131.95% | 127.53% | 132.59% | 103.17% | 114.02% | 114.30% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
12.70% | 15.47% | 17.32% | 21.67% | 18.71% | 16.25% | 11.09% | 4.17% | 3.00% | 3.32% |
Graham Net Nets |
0.18 | 0.25 | 0.19 | 0.17 | 0.16 | 0.19 | 0.11 | 0.53 | (1.92) | (1.92) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(2.23%) | (5.42%) | (5.47%) | (13.44%) | (7.65%) | (5.08%) | (7.21%) | (17.19%) | (24.76%) | (24.76%) |
Free Cash Flow Yield |
(1.07%) | (3.94%) | (3.31%) | (11.23%) | (6.24%) | (3.82%) | (6.41%) | (9.31%) | (17.61%) | (17.61%) |
Revenue per Share |
4.68 | 4.03 | 3.61 | 3.11 | 2.72 | 2.53 | 2.72 | 6.97 | 13.84 | 12.70 |
Operating CF per Share |
(0.02) | (0.30) | (0.49) | (1.22) | (1.19) | (1.06) | (1.28) | (1.83) | (5.06) | (5.06) |
Capex per Share |
(0.20) | (0.25) | (0.20) | (0.28) | (0.19) | (0.09) | (0.10) | (0.12) | (0.14) | (0.13) |
Free Cash Flow per Share |
(0.21) | (0.55) | (0.69) | (1.50) | (1.39) | (1.14) | (1.38) | (1.94) | (5.19) | (5.19) |
Cash per Share |
3.44 | 3.62 | 4.32 | 2.84 | 4.43 | 6.76 | 3.71 | 15.37 | 6.46 | 8.42 |
Shareholders Equity per Share |
4.13 | 4.03 | 4.41 | 2.87 | 4.06 | 5.83 | 2.55 | 11.34 | (37.32) | (32.81) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.13 | 4.03 | 4.41 | 2.87 | 4.06 | 5.83 | 2.55 | 11.34 | (37.32) | (32.81) |
Free Cash Flow |
(9.09) | (22.92) | (26.51) | (51.16) | (45.92) | (33.22) | (34.07) | (15.46) | (18.01) | (17.19) |
Working Capital |
190.84 | 180.65 | 187.94 | 116.43 | 158.98 | 204.77 | 92.69 | 127.04 | 26.09 | 22.94 |
Capital Expenditures |
(8.41) | (10.50) | (7.80) | (9.51) | (6.39) | (2.56) | (2.44) | (0.94) | (0.48) | (0.44) |
Net Current Asset Value |
155.09 | 144.31 | 150.34 | 78.36 | 119.78 | 164.46 | 57.46 | 87.71 | (131.58) | (111.84) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.04 | 0.06 | 0.06 | 0.09 | 0.07 | 0.03 | 0.04 | 0.02 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | (0.04) | 0.10 | 0.25 | 0.41 | 0.34 | 0.26 | 0.46 | 0.68 | 0.51 |
Cash ROIC |
(2.52%) | (6.50%) | (7.14%) | (22.17%) | (14.52%) | (8.20%) | (17.56%) | (6.15%) | 26.38% | 33.37% |
Accounts Receivable Turnover |
7.00 | 6.77 | 6.52 | 6.09 | 6.47 | 5.79 | 6.66 | 6.97 | 7.18 | 6.30 |
Accounts Payable Turnover |
7.38 | 6.33 | 5.42 | 3.31 | 3.22 | 2.93 | 2.74 | 2.44 | 3.60 | 3.64 |
Inventory Turnover |
1.35 | 1.48 | 1.57 | 1.09 | 1.22 | 1.61 | 1.54 | 1.64 | 2.51 | 2.54 |
Average Days of Payables |
41.18 | 67.55 | 56.83 | 145.93 | 111.94 | 134.12 | 151.11 | 162.07 | 129.52 | 72.43 |
Days of Inventory on Hand |
301.43 | 281.88 | 250.83 | 401.65 | 402.45 | 230.96 | 293.08 | 252.47 | 182.29 | 106.99 |
Average Receivables |
28.69 | 24.71 | 21.31 | 17.46 | 13.93 | 12.67 | 10.10 | 7.95 | 6.68 | 6.68 |
Average Payables |
5.56 | 5.54 | 5.43 | 4.74 | 3.23 | 3.04 | 2.48 | 1.98 | 1.42 | 1.42 |
Average Inventory |
30.49 | 23.66 | 18.77 | 14.39 | 8.57 | 5.54 | 4.40 | 2.95 | 2.03 | 2.03 |
Average Assets |
234.50 | 230.43 | 193.99 | 174.03 | 206.82 | 170.08 | 127.77 | 87.18 | 37.64 | 37.64 |
Average Common Equity |
172.25 | 168.17 | 133.84 | 116.36 | 151.89 | 116.19 | 76.60 | (19.59) | (119.06) | (119.06) |
Columns are period end dates